The European Union Drugs Agency has published its European Drug Report 2026, drawing on data from 29 countries. Overall, the picture it paints is not encouraging. Illicit drugs remain widely available, markets keep diversifying, and thousands of people are still dying every year. None of this will surprise anyone who works in drug prevention in Europe. It simply confirms what the evidence has shown for years. Enforcement on its own cannot close this gap, and reactive measures cannot substitute for stopping use before it starts.
A Market That Keeps Outrunning Enforcement
Cannabis remains Europe’s most used illicit drug, though the product itself has changed considerably. High potency cannabis imported from North America prompted the EUDA’s first ever alert in November 2025. The alert, issued under the European Drug Alert System, followed reports of contamination and unpredictable strength. Meanwhile, semi synthetic cannabinoids such as HHC are adding to the uncertainty over what people are actually consuming.
Cocaine tells a similar story. Spain seized 124 tonnes in 2024, while France reported its largest haul on record at 53.5 tonnes. Yet trafficking networks simply adapted, shifting toward smaller ports, drones and semi submersible vessels to stay ahead of enforcement. New psychoactive substances are multiplying just as fast. Fifty were detected for the first time in 2025 alone, several of them potent synthetic opioids. The total now monitored by the EUDA has passed 1,050. Ketamine use is climbing too, with wastewater testing across European cities pointing to use spreading beyond its traditional nightlife setting.
In short, none of this looks like a market under control. It looks like one that keeps outrunning the response.
The Toll Keeps Climbing
At least 7,600 people died from drug overdoses across the EU in 2024. Most of those deaths involved more than one substance. Opioids remain the leading cause, usually taken alongside other drugs. Such polysubstance use is exactly the unpredictable pattern the report identifies as a growing risk.
Injecting drug use has declined over the past decade. It still drives a disproportionate share of blood borne infections, including HIV and hepatitis. Around 505,000 people were in opioid agonist treatment across 26 EU member states in 2024. The figure has essentially plateaued rather than fallen. Dependency, in other words, is not resolving on its own.
Why Drug Prevention in Europe Has to Come First
None of this happens in isolation. The report points to criminal networks recruiting and exploiting vulnerable young people to move drugs and enforce control through violence. Novel substances, meanwhile, keep outpacing regulation before health authorities even understand the risks involved. Waiting until someone is already dependent, then managing the fallout, cannot remain Europe’s default approach.
Genuine drug prevention in Europe means stopping use before it starts. This includes early intervention with children and adolescents, and education that builds resistance rather than curiosity. It also means demand reduction efforts that shrink the market pulling young people in. Supply side enforcement clearly has a role, given the scale of the seizures reported. Even so, it has not been enough on its own to slow the trend.
Harm reduction services such as needle exchanges, take home naloxone and opioid agonist treatment do save lives in the moment. The report catalogues an extensive network of them across Europe. But they are reactive by design, managing consequences rather than reducing how many people start in the first place. They were never meant to stand in for prevention.
Drug Prevention in Europe Means Real Recovery, Not Maintenance
Half a million people in long term opioid agonist treatment is not, by itself, a success story. The report notes that treatment goals can range from harm reduction to full abstinence and social reintegration. Yet the balance across Europe still leans heavily toward maintenance rather than exit. A prevention focused response has to include a genuine pathway out of dependency, not indefinite management of it.
The EU’s own Drugs Strategic Framework, endorsed in March 2026, calls for a balanced approach to supply and demand. Taken together, the data in this report make the case plainly. Enforcement alone has not shrunk Europe’s drug markets. Prevention, early intervention and recovery pathways must carry equal weight, or next year’s numbers will look the same.
Leave a Reply